| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Bristol-Myers Squibb Pharmaceutical Research Institute, Department of Oncology Drug Discovery, Princeton, New Jersey 08543 [D. K. B., R. B. R., C-P. H., B. P., J. D., M. S.], and University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas 78957 [K. K., S. M., R. K., S. M. F.]
Significant evidence has accumulated suggesting that the inducible formof cyclooxygenase (COX-2), a central enzyme in the prostaglandin biosynthetic pathway, plays an important role in tumor development. To better understand the role of COX-2 in tumorigenesis, we generated transgenic mice that overexpress COX-2 under control of the human keratin 14 promoter, which allows for expression in the epidermis and some other epithelia. Transgenic mice, referred to as K14.COX2 mice, were readily distinguished from their nontransgenic littermates by the appearance of significant alopecia. Administration of a specific COX-2 inhibitor restored hair growth, indicating that the alopecia was attributable to elevated COX-2 enzymatic activity. Unexpectedly, COX-2 overexpression was found to protect, rather than sensitize, K14.COX2 mice to skin tumor development induced by an initiation/promotion protocol. K14.COX2 transgenics developed tumors at a much lower frequency than did their littermate controls (3.3% versus 93%, respectively, on a FVB background and 
25% versus 100%, respectively, on an ICR background) and presented with significantly reduced tumor burdens (average, 0.03 versus 12.7 tumors/mouse, respectively, on a FVB background and 0.5 versus 7.1 tumors/mouse, respectively, on an ICR background). Mice fed a COX-2 inhibitor in utero and as weanlings up to the time of promotion also showed a significant resistance to tumor development. These results clearly raise questions regarding the role of COX-2 and elevated prostaglandin levels in skin tumor development.
This article has been cited by other articles:
|
|
 |
|
  J. Y. Tang, M. Aszterbaum, M. Athar, F. Barsanti, C. Cappola, N. Estevez, J. Hebert, J. Hwang, Y. Khaimskiy, A. Kim, et al. Basal Cell Carcinoma Chemoprevention with Nonsteroidal Anti-inflammatory Drugs in Genetically Predisposed PTCH1+/- Humans and Mice Cancer Prevention Research, January 1, 2010; 3(1): 25 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Kwon, K. W. Lee, J.-E. Kim, S. K. Jung, N. J. Kang, M. K. Hwang, Y.-S. Heo, A. M. Bode, Z. Dong, and H. J. Lee Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MAPKK4 and PI-3 kinase Carcinogenesis, November 1, 2009; 30(11): 1932 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Elrod, P. Yue, F. R. Khuri, and S.-Y. Sun Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism Mol. Cancer Ther., September 1, 2009; 8(9): 2575 - 2585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Greenhough, H. J.M. Smartt, A. E. Moore, H. R. Roberts, A. C. Williams, C. Paraskeva, and A. Kaidi The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis, March 1, 2009; 30(3): 377 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Fernandez, P. M. de Beer, L. van der Merwe, and C. F. Heyns COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men Carcinogenesis, December 1, 2008; 29(12): 2347 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Ansari, J. E. Rundhaug, and S. M. Fischer Multiple Signaling Pathways Are Responsible for Prostaglandin E2-Induced Murine Keratinocyte Proliferation Mol. Cancer Res., June 1, 2008; 6(6): 1003 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhang, J. Li, L. Song, W. Ouyang, J. Gao, and C. Huang A JNK1/AP-1-Dependent, COX-2 Induction Is Implicated in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Cell Transformation through Regulating Cell Cycle Progression Mol. Cancer Res., January 1, 2008; 6(1): 165 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wan, A. Saghatelian, L.-W. Chong, C.-L. Zhang, B. F. Cravatt, and R. M. Evans Maternal PPAR{gamma} protects nursing neonates by suppressing the production of inflammatory milk Genes & Dev., August 1, 2007; 21(15): 1895 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Meng, S. Ceryak, Z. Aratsu, L. Jones, L. Epstein, and B. Bouscarel Biphasic regulation by bile acids of dermal fibroblast proliferation through regulation of cAMP production and COX-2 expression level Am J Physiol Cell Physiol, September 1, 2006; 291(3): C546 - C554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Tang, A. Shih, H. J. Cao, F. B. Davis, P. J. Davis, and H.-Y. Lin Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther., August 1, 2006; 5(8): 2034 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Xu, S. Choudhary, O. Voznesensky, M. Mehrotra, M. Woodard, M. Hansen, H. Herschman, and C. Pilbeam Overexpression of Cox-2 in Human Osteosarcoma Cells Decreases Proliferation and Increases Apoptosis. Cancer Res., July 1, 2006; 66(13): 6657 - 6664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Aziz, D. L. Wheeler, B. Bhamb, and A. K. Verma Protein Kinase C {delta} Overexpressing Transgenic Mice Are Resistant to Chemically but not to UV Radiation-Induced Development of Squamous Cell Carcinomas: A Possible Link to Specific Cytokines and Cyclooxygenase-2 Cancer Res., January 15, 2006; 66(2): 713 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rigas and K. Kashfi Cancer Prevention: A New Era beyond Cyclooxygenase-2 J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Dwyer-Nield, M. C. Srebernak, B. S. Barrett, J. Ahn, P. Cosper, A. M. Meyer, L. R. Kisley, A. K. Bauer, D. C. Thompson, and A. M. Malkinson Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines Carcinogenesis, July 1, 2005; 26(7): 1196 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pozzi, X. Yan, I. Macias-Perez, S. Wei, A. N. Hata, R. M. Breyer, J. D. Morrow, and J. H. Capdevila Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation J. Biol. Chem., July 9, 2004; 279(28): 29797 - 29804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-S. Chun, H.-H. Cha, J.-W. Shin, H.-K. Na, K.-K. Park, W.-Y. Chung, and Y.-J. Surh Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NF-{kappa}B Carcinogenesis, March 1, 2004; 25(3): 445 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. KUWANO, S. NAKAO, H. YAMAMOTO, M. TSUNEYOSHI, T. YAMAMOTO, M. KUWANO, and M. ONO Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis FASEB J, February 1, 2004; 18(2): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Raju and R. P. Bird Energy Restriction Reduces the Number of Advanced Aberrant Crypt Foci and Attenuates the Expression of Colonic Transforming Growth Factor {beta} and Cyclooxygenase Isoforms in Zucker Obese (fa/fa) Rats Cancer Res., October 15, 2003; 63(20): 6595 - 6601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Klatt and M. Serrano Engineering cancer resistance in mice Carcinogenesis, May 1, 2003; 24(5): 817 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. DuBois Evaluation of the Whole Prostaglandin Biosynthetic Pathway in Lung Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1577 - 1578. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hardy, E. A. G. Blomme, A. Lisowski, K. S. Chinn, A. Jones, J. M. Harmon, A. Opsahl, R. L. Ornberg, and C. S. Tripp Selective Cyclooxygenase-2 Inhibition Does Not Alter Keratinocyte Wound Responses in the Mouse Epidermis after Abrasion J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 959 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zeng, L. K. McCauley, and C.-Y. Wang Hepatocyte Growth Factor Inhibits Anoikis by Induction of Activator Protein 1-dependent Cyclooxygenase-2. IMPLICATION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA PROGRESSION J. Biol. Chem., December 13, 2002; 277(51): 50137 - 50142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Willis and N. H. Colburn Molecular Targets for Cancer Prevention: A Meeting Review of the Third American Cancer Society-Schilling Research Conference Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 972 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Muller-Decker, G. Neufang, I. Berger, M. Neumann, F. Marks, and G. Furstenberger Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis PNAS, September 17, 2002; 99(19): 12483 - 12488. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
